VIVOSIM LABS INC

VIVOSIM LABS INC’s bio‑printing venture faces steep financial hurdles—negative P/E, $1.2 M cap, volatile price swings—highlighting the biotech sector’s risk‑reward reality.

VivoSim Labs secures its first NAMkind sales in China, boosting global predictive toxicology adoption and aligning with new non‑animal testing regulations.

VivoSim Labs expands its NAMKind toxicology platform into Asia‑Pacific via JCBio and Tekon Biotech, delivering 30‑day human‑based liver & GI safety insights for faster drug development.